Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients

Abstract

Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing, impairing our capacity to personalize and guide treatment. Therefore, this paper aims to analyze the most promising emerging predictive biomarkers that could help us in the near future to select patients more effectively.

Keywords

• advanced NSCLC
• immunotherapy
• predictive biomarkers
• PD-L1
• TMB
• TILS